Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06725-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Secondo Lastoria und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, IRCCS Istituto Nazionale Tumori, "Fondazione Senatore Giovanni Pascale", Naples, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms, Octreotide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [ 177 Lu]-DOTA-TATE was approved for the treatment of GEP-NETs after the phase III NETTER 1trial demonstrated improved progression free survival, objective response rates and health-related quality of life (HRQoL) compared to high-dose somatostatin analogues. No real-world data exist on prescribing habits and clinically significant endpoints for [ 177 Lu]Lu-DOTA-TATE treatment in Italy. REAL-LU is a multicentre, long-term observational study in patients with unresectable/metastatic GEP-NETs progressing on standard therapies in Italian clinical practice. A pre-specified interim analysis was performed at the end of the enrolment period, data from which are described herein.
Methods
Overall duration of REAL-LU will be approximately 48 months, with 12- and 36-month recruitment and follow-up periods, respectively. The primary objective is to evaluate [ 177 Lu]Lu-DOTA-TATE effectiveness in terms of progression-free survival. Secondary objectives include safety, impact on HRQoL, and identification of prognostic factors. This pre-specified interim analysis describes patient profiles, at the end of enrollment, of those prescribed [ 177 Lu]Lu-DOTA-TATE for GEP-NETs in Italy.
Results
Among 161 evaluable patients, mean age was 64.7 ± 10.3 years at study entry, 83.8% presented with no clinical signs of disease at physical examination, and most had minor disease symptoms. All patients had metastatic disease, most commonly in the liver (83.9%) with a median of two metastatic sites. In 90.7% of patients, the disease was stage IV, and 68.3% had ≥ 1 target lesion. [ 177 Lu]Lu-DOTA-TATE was prescribed mainly as second-line therapy (61.6%) and following surgery (58.4%). HRQoL assessments revealed high levels of functioning and low levels of symptoms at baseline; 50.0% of patients were symptom-free at study entry.
Conclusion
The characteristics of patients who received [177Lu]Lu-DOTA-TATE in Italy are similar to those of the GEP-NET population of NETTER 1 with trial but with a higher proportion of patients with a grade 2 (71%). With regard to the tumor grade profile, our study cohort appears to be closer to that of NETTER-2 study population which included patients with G2 or G3 advanced GEP-NETs (i.e. Ki-67 ≥ 10% and ≤ 55%). Further analysis of effectiveness and safety can be anticipated as REAL-LU data mature. Study Registration: ClinicalTrials.gov, NCT04727723; Study Registration Date: 25 January, 2021; https://clinicaltrials.gov/study/NCT04727723?cond=NCT04727723&rank=1
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nuclear Medicine, IRCCS Istituto Nazionale Tumori, "Fondazione Senatore Giovanni Pascale", Naples, Italy.
- Nuclear Medicine Unit, IRCCS-Humanitas Clinical and Research Hospital, Rozzano, MI, Italy.
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy.
- Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy. sbaldari@unime.it.
- U.O.C. Medicina Nucleare-Ospedale "S.M. Goretti", Latina, Italy.
- Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
ORCID-Profile: Secondo Lastoria, Marcello Rodari, Maddalena Sansovini, Sergio Baldari, Anna Rita Cervino, Angelina Filice, Matteo Salgarello, Germano Perotti, Alberto Nieri, Davide Campana, Valeria Gaudieri, Giovanni Storto, Chiara Maria Grana, Alberto Signore, Giuseppe Boni, Francesco Dondi, Gabriele Simontacchi, Ettore Seregni
Zitieren
APA
Lastoria, S., Rodari, M., Sansovini, M., Baldari, S., D'Agostini, A., Cervino, A. R., Filice, A., Salgarello, M., Perotti, G., Nieri, A., Campana, D., Pellerito, R. E., Pomposelli, E., Gaudieri, V., Storto, G., Grana, C. M., Signore, A., Boni, G., Dondi, F., …, & Seregni, E. (2024). Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06725-7
Vancouver
Lastoria S, Rodari M, Sansovini M, Baldari S, D'Agostini A, Cervino AR, et al. Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06725-7
BibTeX
@article{Lastoria2024,
author = {Lastoria, Secondo and Rodari, Marcello and Sansovini, Maddalena and Baldari, Sergio and D'Agostini, Antonio and Cervino, Anna Rita and Filice, Angelina and Salgarello, Matteo and Perotti, Germano and Nieri, Alberto and Campana, Davide and Pellerito, Riccardo Emanuele and Pomposelli, Elena and Gaudieri, Valeria and Storto, Giovanni and Grana, Chiara Maria and Signore, Alberto and Boni, Giuseppe and Dondi, Francesco and Simontacchi, Gabriele and Seregni, Ettore},
title = {Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06725-7}
}
EUVIMED